Denali Therapeutics shares reversed higher on Tuesday after the drugmaker's ALS treatment failed in a six-month study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback